What is Gennex Laboratories Ltd (531739) share price return in the past 10 years?

Gennex Laboratories Ltd share price has appreciated 4.4% annually (CAGR) over the past ten years.

What is the share price of Gennex Laboratories Ltd (531739)?

Company share prices are keep on changing according to the market conditions. The current trading price of Gennex Laboratories Ltd (531739) on 03-Jul-2026 16:59:59 at 16:59 is 10.16.

What is the P/E ratio of Gennex Laboratories?

The latest standalone P/E ratio of Gennex Laboratories as of 03-Jul-2026 is 15.30.

What is the P/B ratio of Gennex Laboratories Ltd (531739)?

The latest standalone P/B ratio of Gennex Laboratories Ltd (531739) as of 03-Jul-2026 is 1.13.

What is the 52-week high and low of Gennex Laboratories Ltd (531739)?

The 52-week high of Gennex Laboratories Ltd (531739) is Rs. 17.25 and the 52-week low is Rs. 7.05.

Gennex Laboratories Ltd (531739) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Gennex Laboratories Ltd (531739)
Brand: Gennex Laboratories

Gennex Laboratories Ltd (531739)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531739 NSE: Pharmaceuticals & Drugs | Small Cap | Gennex Laboratories Share Price

Gennex Laboratories Ltd (531739)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531739 NSE: Pharmaceuticals & Drugs | Small Cap | Gennex Laboratories Share Price

Key Metrics

Valuation Multiples

Market Cap

₹247 Cr.

Current Price

₹10.2

52-Week Low / High

₹7 / 17

TTM EPS

₹0.7

TTM Sales

₹120 Cr.

Book Value per Share

₹9

P/E Ratio

15.30

Lower than its 5-year historical median

Industry PE

49.8

Price to Book (P/B)

1.13

Lower than its 5-year historical median

Price to Sales (P/S)

2.06

Lower than its 5-year historical median

EV/EBITDA

9.75

Lower than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

8.16%

Underperforms industry median

Return on Capital Employed (ROCE)

10.25%

Underperforms industry median

Return on Assets (ROA)

6.63%

Operating Profit Margin

10.9%

Net Profit Margin

14.84%

Gross Profit Margin

17.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

41.59%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-16.91%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

18.98%

Asset Quality

Promoter Holding

23.63%

Pledged shares (%) of Promoter's holding (%)

17.42%

Reserves

₹194 Cr.

Equity

₹24.3 Cr.

Face Value

₹1

All Time Low / High

₹0.22 / 29.00

Gennex Laboratories stock performance

Key Ratios

Check Before You Invest

Quality

Locked

Valuation

Locked

Price Trend

Locked

Q.1 Is Gennex Laboratories Ltd a good quality company?

Gennex Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Gennex Laboratories Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Gennex Laboratories Ltd vs industry peers?

Gennex Laboratories Ltd revenue CAGR is 11.20%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Gennex Laboratories Ltd?

Promoters hold 23.63% of the Gennex Laboratories Ltd, with 17.42% of their stake pledged, indicating high pledge risk.

Q.1 Stock return of Gennex Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 6.6% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	11.8%	11.6%	6.3%	10.5%	8.3%	13.2%	11.8%	10.7%	12.5%	10.3%	-
Value Creation Index ⓘ	-0.2	-0.2	-0.6	-0.3	-0.4	-0.1	-0.2	-0.2	-0.1	-0.3	-
Growth Parameters ⓘ
Sales ⓘ	38.6	41.9	43.8	55.8	55.6	59.7	61.2	65.1	66.8	94.6	120
Sales YoY Gr.	-	8.7%	4.5%	27.5%	-0.3%	7.3%	2.6%	6.4%	2.6%	41.6%	-
Adj EPS ⓘ	0.2	0.2	0.1	0.2	0.1	0.3	0.3	0.2	0.5	0.6	0.7
YoY Gr.	-	16.7%	-71.4%	183.3%	-29.4%	158.3%	-9.7%	-14.3%	112.5%	21.6%	-
BVPS (₹) ⓘ	2.1	2.3	2.4	2.6	2.7	3	3.3	4.5	7.3	7.9	9
Adj Net Profit ⓘ	2.4	2.7	0.9	2.2	1.6	4.1	3.7	4.2	11.7	14	16
Cash Flow from Ops. ⓘ	3.4	-0.1	3.2	1.9	-1.7	-1.4	6.6	-14.5	-33.4	-9.5	-
Debt/CF from Ops. ⓘ	0.7	-36.2	0.8	2.4	-3	-5.1	1.5	-0.2	-0.1	-0.6	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.5%	11.2%	15.6%	41.6%
Adj EPS ⓘ	14.7%	38.9%	30.3%	21.6%
BVPSⓘ	15.6%	23.9%	33.3%	8.4%
Share Price	4.4%	-0.9%	14.2%	-17.9%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	8.7	9.2	2.7	6.7	4.7	10.7	8.7	6.9	9.4	7.9	7.8
Op. Profit Mgn % ⓘ	10.9	10.9	5.2	7.2	5.8	11	8.8	7	18.6	10.9	15.6
Net Profit Mgn % ⓘ	6.1	6.5	2	4	2.9	6.8	6	6.5	17.5	14.8	13.4
Debt to Equity ⓘ	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0	0	0	0
Working Cap Days ⓘ	160	185	203	161	184	204	213	249	436	435	325
Cash Conv. Cycle ⓘ	6	10	2	15	33	25	43	70	59	59	254

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	39	42	44	56	56	60	61	65	67	95
Operating Expenses ⓘ +	34	37	42	52	52	53	56	61	54	84
Manufacturing Costs	5	5	6	8	8	6	6	8	6	5
Material Costs	23	24	27	33	34	36	38	40	38	66
Employee Cost	4	5	6	6	7	7	7	8	6	6
Other Costs ⓘ	3	4	4	5	4	4	4	5	4	6
Operating Profit ⓘ	4	5	2	4	3	7	5	5	12	10
Operating Profit Margin (%)	10.9%	10.8%	5.0%	7.2%	5.8%	11.0%	8.8%	7.0%	18.6%	10.9%
Other Income ⓘ +	0	0	1	1	1	1	1	3	4	9
Exceptional Items ⓘ	-0	0	0	0	0	-0	0	0	0	-0
Interest ⓘ	1	1	1	1	1	1	1	1	1	2
Depreciation ⓘ	1	1	1	1	1	1	1	1	1	1
Profit Before Tax ⓘ	3	3	1	3	3	5	5	6	15	17
Tax ⓘ	1	0	1	1	1	1	1	1	3	3
Profit After Tax	2	3	1	2	2	4	4	5	12	14
PAT Margin (%)	6.1%	6.5%	1.9%	4.0%	3.3%	6.8%	6.4%	7.0%	17.7%	14.8%
Adjusted EPS (₹)	0.2	0.2	0.1	0.2	0.1	0.3	0.3	0.3	0.5	0.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Gennex Laboratories - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	28	31	32	34	36	40	44	79	165	179
Share Capital ⓘ	13	13	13	13	13	13	13	18	23	23
Reserves ⓘ	16	18	19	21	23	27	31	61	142	156
Debt +	2	4	3	5	5	7	10	2	3	6
Long Term Debt	0	0	0	0	0	0	0	1	2	4
Short Term Debt	2	4	2	5	5	7	10	1	1	1
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	7	9	12	8	8	6	8	6	14	11
Others Liabilities ⓘ	4	5	4	5	8	6	6	8	23	23
Total Liabilities ⓘ	42	49	50	52	57	59	68	96	205	218
Fixed Assets
Net Fixed Assets ⓘ +	15	16	16	16	15	14	14	15	16	20
Gross Block	27	28	29	30	30	30	31	33	34	39
Accumulated Depreciation	12	12	13	14	15	16	17	17	18	19
CWIP ⓘ	0	0	0	0	0	0	0	0	1	3
Investments ⓘ	7	7	7	7	7	7	7	8	8	8
Inventories	3	3	2	5	7	5	8	15	16	25
Trade Receivables	7	10	10	10	6	8	11	9	14	12
Cash Equivalents ⓘ	1	1	1	3	1	1	8	14	61	56
Others Assets ⓘ	8	13	14	10	21	24	20	34	89	96
Total Assets ⓘ	42	49	50	52	57	59	68	96	205	218

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	3	-0	3	2	-2	-1	7	-14	-33	-10
PBT ⓘ	3	3	1	3	3	5	5	6	15	17
Adjustment ⓘ	1	2	2	2	2	2	3	-1	-2	-6
Changes in Working Capital ⓘ	-1	-4	1	-3	-6	-7	-0	-20	-45	-21
Tax Paid ⓘ	-0	-1	-1	-0	-0	-2	-1	0	-1	0
Cash Flow From Investing Activity ⓘ +	-1	-1	-1	-1	-0	-0	-1	-1	1	3
Capex	-1	-1	-1	-1	-0	-0	-0	-2	-3	-6
Net Investments	0	0	0	0	0	0	0	-1	0	0
Others ⓘ	0	0	0	0	0	0	-1	3	4	8
Cash Flow From Financing Activity ⓘ +	-2	1	-2	1	-0	2	2	21	79	2
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	30	80	0
Net Proceeds from Borrowing ⓘ	0	0	0	-0	-0	-0	-0	1	0	3
Interest Paid ⓘ	-1	-1	-1	-1	-1	-1	-1	-1	-1	-2
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-1	2	-2	2	0	2	3	-9	-0	0
Net Cash Flow ⓘ	0	-0	0	2	-2	0	7	6	47	-5

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	8.69	9.14	2.67	6.75	5.32	10.66	9.35	7.43	9.68	8.16
ROCE (%)	11.78	11.61	6.31	10.49	8.32	13.18	11.78	10.7	12.5	10.25
Asset Turnover Ratio	1	0.96	0.95	1.17	1.1	1.1	1.03	0.87	0.49	0.5
PAT to CFO Conversion(x)	1.5	-0	3	1	-1	-0.25	1.75	-2.8	-2.75	-0.71
Working Capital Days
Receivable Days	59.50	72.40	80.10	63.50	50.80	40	53.10	51.50	55.20	44.20
Inventory Days	19.10	24.50	20.20	23.30	38.90	35.70	35.70	58.10	76.50	70.60
Payable Days	111.30	125.90	147.60	113.40	88.40	71.90	65.60	65.10	99	69.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

23.87

21.79

17.43

17.42

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gennex Laboratories Ltd FAQs

The current trading price of Gennex Laboratories on 03-Jul-2026 16:59 is ₹10.16.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 02-Jul-2026 the market cap of Gennex Laboratories stood at ₹246.8 Cr

The latest P/E ratio of Gennex Laboratories as of 02-Jul-2026 is 15.30.

The latest P/B ratio of Gennex Laboratories as of 02-Jul-2026 is 1.13.

The 52-week high of Gennex Laboratories is ₹17.25 and the 52-week low is ₹7.05.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gennex Laboratories is ₹120 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Gennex Laboratories Ltd is a below average quality company.

The key valuation ratios of Gennex Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gennex Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Gennex Laboratories Ltd

Gennex Laboratories (formerly Prudential Pharmaceuticals) is a public limited company established in the year 1995 and has been engaged in the manufacturing of bulk drugs and intermediates. The company started as one of the leading manufacturer and exporter of bulk drugs and intermediates. Quality is the strength of the company and major part of its finished products are exported to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and other major countries. Gennex Laboratories has diversified its activities to biotech products in order to have better prospects and opportunities for the company for expanding its bussiness activities and to meet the marketing requirements.

The company had commenced its commercial operations of Guaifenesin in November, 1995 and in a span of about one and half years, it was able to capture about 70% of the domestic market mainly due to the impeccable quality, aggressive marketing strategies, cost effective manufacturing and efficient distribution cum market penetration. It has also established itself fairly well in the export market and recognized well by many end-users and trading giants of international market.

The company has catered to countries like USA, Mexico, Spain and Germany and the quality has been accepted and appreciated extremely well with all the customers. Several customers have evinced interest on long-term tie-ups. Slowly but surely, the company is constantly expanding its reach to USA and European markets and it has been receiving very encouraging enquiries from prospective customers based on quality recommendations by existing customers. The companyâ€™s headquarters is situated in the heart of the city and the factory is situated at Survey No 133, IDA Bollaram, Jinnaram Mandal, Medak District-502 325, Andhra Pradesh, India. The factory occupies a total land area of 8,000 square meters. The total building floor space is1,945 square meters. The storage space is 500 square meters. The central lab has a floor space of 225 square meters.

Products of the company:

Guaiphenesin
Methocarbamol
Fluconazole
Phenazopyridine

Certification:

Gennex Laboratories is an ISO 9001: 2008 approved company and obtained GMP Certification from the Central Drug Authority.
The company is also planning for ISO 14001: 2002 certification and OHSHAS 18000 to ensure its products are more widely accepted in the international market.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Gennex Laboratories Ltd (531739)

Gennex Laboratories Ltd (531739)

Gennex Laboratories stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Gennex Laboratories - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Gennex Laboratories Ltd FAQs

What is the share price of Gennex Laboratories?

What is the market cap of Gennex Laboratories?

What is the P/E ratio of Gennex Laboratories?

What is the P/B ratio of Gennex Laboratories?

What is the 52-week high and low of Gennex Laboratories?

What is the TTM revenue of Gennex Laboratories?

Is Gennex Laboratories Ltd a good quality company?

Is Gennex Laboratories Ltd undervalued or overvalued?

Is Gennex Laboratories Ltd a good buy now?

About Gennex Laboratories Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.